VEXTF (Vext Science) Debt-to-Revenue : 0.97 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Vext Science Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Vext Science's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $5.47 Mil. Vext Science's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $34.04 Mil. Vext Science's annualized Revenue for the quarter that ended in Dec. 2024 was $40.78 Mil. Vext Science's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.97.

Vext Science Debt-to-Revenue Historical Data

The historical data trend for Vext Science's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vext Science Debt-to-Revenue Chart

Vext Science Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Revenue

Get a 7-Day Free Trial

0.46

0.38

1.08

1.11

1.10

Vext Science Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Revenue	Get a 7-Day Free Trial															1.15	1.16	1.14	1.12	0.97

Competitive Comparison of Vext Science's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vext Science's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vext Science's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Vext Science's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

Vext Science Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Vext Science's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(5.474	+	34.043)	/	35.998
	=	1.10

Vext Science's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(5.474	+	34.043)	/	40.776
	=	0.97

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.

Vext Science Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Vext Science's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Vext Science Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vext Science Inc (OTCPK:VEXTF) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

VV5:Germany VEXT:Canada

Address

4152 N. 39th Avenue, Admin, Phoenix, AZ, USA, 85019

Website

https://www.vextscience.com

Vext Science Inc provides management, advisory, cultivation, and dispensary services to entities in the medical cannabis field. The company's expertise spans from cultivation through to retail operations. Its revenue sources include management fees, professional services, product sales, equipment leasing and property leasing. The company's operations consist of a single operating segment engaged in the cultivation, manufacturing, distribution and sale of cannabis within the United States.